GlassScriptPhysician profile
Ejiro E Ughovwa
NPI 1770521536
$3,689.78
in general payments reported to CMS, 2019-2025
31 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $254 · 2021: $393 · 2022: $438 · 2023: $659 · 2024: $973 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.02 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,380.37 | 2020-2025 | Vraylar, Ubrelvy, Viberzi |
| Astellas Pharma US INC | $268.47 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $171.29 | 2019-2024 | |
| Novo Nordisk INC | $162.52 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $156.18 | 2020-2024 | |
| Axsome Therapeutics, INC. | $154.00 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $152.25 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $144.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $129.38 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.55 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.56 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $90.19 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.62 | 2020-2021 | |
| Exact Sciences Corporation | $63.12 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $46.26 | 2022-2023 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $44.03 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $43.08 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $39.89 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $37.26 | 2023-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $35.73 | 2023 | Qelbree |
| Boston Scientific Corporation | $34.75 | 2019-2022 | |
| Amgen INC. | $33.47 | 2019-2020 | |
| Indivior INC. | $32.25 | 2025 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.01 | 2021-2024 | Jardiance |
| Tolmar, INC. | $21.07 | 2025 | Jatenzo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.21 | 2025 | |
| Evofem Biosciences, INC. | $18.01 | 2025 | Solosec, Phexx, Phexxi |
| Sunovion Pharmaceuticals INC. | $16.00 | 2019 | |
| Ardelyx, INC. | $15.73 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $15.00 | 2019 | |
| Allergan, INC. | $13.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ejiro Ughovwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.